EGF receptor (EGFR)-targeted monoclonal antibodies are effective in a subset of metastatic colorectal cancers. Inevitably, all patients develop resistance, which occurs through emergence of KRAS mutations in approximately 50% of the cases. We show that amplification of the MET proto-oncogene is associated with acquired resistance in tumors that do not develop KRAS mutations during anti-EGFR therapy. Amplification of the MET locus was present in circulating tumor DNA before relapse was clinically evident. Functional studies show that MET activation confers resistance to anti-EGFR therapy both in vitro and in vivo. Notably, in patient-derived colorectal cancer xenografts, MET amplification correlated with resistance to EGFR blockade, which could be overcome by MET kinase inhibitors. These results highlight the role of MET in mediating primary and secondary resistance to anti-EGFR therapies in colorectal cancer and encourage the use of MET inhibitors in patients displaying resistance as a result of MET amplification. SIGNIFICANCE: Amplification of the MET proto-oncogene is responsible for de novo and acquired resistance to anti-EGFR therapy in a subset of colorectal cancers. As multiple anti-MET therapeutic strategies are available, these findings offer immediate novel opportunities to design clinical studies.
Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer / A. Bardelli, S. Corso, A. Bertotti, S. Hobor, E. Valtorta, G. Siravegna, A. Sartore Bianchi, E. Scala, A. Cassingena, D. Zecchin, M. Apicella, G. Migliardi, F. Galimi, C. Lauricella, C. Zanon, T. Perera, S. Veronese, G. Corti, A. Amatu, M. Gambacorta, D. J. Luis A., M. Sausen, V.E. Velculescu, P. Comoglio, L. Trusolino, F. Di Nicolantonio, S. Giordano, S. Siena. - In: CANCER DISCOVERY. - ISSN 2159-8274. - 3:6(2013 Jun), pp. 658-673.
|Titolo:||Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer|
|Parole Chiave:||Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Colorectal Neoplasms; Drug Resistance, Neoplasm; Genes, ras; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Proto-Oncogene Proteins c-met; Random Allocation; Receptor, Epidermal Growth Factor; Xenograft Model Antitumor Assays; Oncology|
|Settore Scientifico Disciplinare:||Settore MED/06 - Oncologia Medica|
|Data di pubblicazione:||giu-2013|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1158/2159-8290.CD-12-0558|
|Appare nelle tipologie:||01 - Articolo su periodico|